PharmaMar and Jazz Pharmaceuticals Announce Initiation of Confirmatory Phase 3 Clinical Trial of Zepzelca® (lurbinectedin) for the Treatment of Patients with Relapsed Small Cell Lung CancerPRNewsWire • 12/13/21
Jazz Pharmaceuticals Presents Positive Interim Phase 2/3 Results of Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at ASH 2021 Annual MeetingPRNewsWire • 12/12/21
Jazz Pharmaceuticals to Present from Expanding Neuroscience Portfolio Epidiolex® (cannabidiol) Oral Solution Data at the 2021 American Epilepsy Society Annual MeetingPRNewsWire • 12/01/21
Jazz Pharmaceuticals Announces First Patient Enrolled in IMforte Phase 3 Trial Evaluating Zepzelca® (lurbinectedin) in Combination with a PD-L1 Inhibitor in Small Cell Lung CancerPRNewsWire • 11/30/21
Going Long On Top Marijuana Stocks To Buy? 3 Of The Best Cannabis Stocks To Watch Right NowMarijuanaStocks • 11/14/21
Jazz Pharmaceuticals PLC (JAZZ) CEO Bruce Cozadd on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/10/21
Jazz Pharmaceuticals (JAZZ) Tops Q3 Earnings and Revenue EstimatesZacks Investment Research • 11/10/21
Jazz Pharmaceuticals Reports Q3 Financial Results, Raises Full-Year Earnings GuidanceBenzinga • 11/09/21
Jazz Pharmaceuticals Announces Third Quarter 2021 Financial Results And Raises Full Year Earnings GuidancePRNewsWire • 11/09/21
Jazz Pharmaceuticals to Present Data Showcasing Clinical Advances Across Hematology/Oncology at ASH 2021 Annual MeetingPRNewsWire • 11/04/21
Jazz Pharmaceuticals to Report 2021 Third Quarter Financial Results on November 9, 2021PRNewsWire • 10/26/21
Jazz Pharmaceuticals: Narcolepsy Franchise Concerns Weigh On Investor SentimentSeeking Alpha • 10/19/21